Largest Phase 3 Trial of Psilocybin for Depression Has Begun | Psychedelic spotlight

As our social fabric is unraveling and rates of depression continue to rise, affecting an estimated 310 million people worldwide, psilocybin research has given us a glimmer of hope that things may be changing for the better.

The largest Phase 3 clinical trial investigating the safety, efficacy, and tolerability of psilocybin as a treatment for treatment-resistant depression (TRD) has finally begun.